Cost–effectiveness of Alternative NTRK Testing Strategies in Cancer Patients Followed by Histology-Independent Therapy with Entrectinib: an Analysis of Three European Countries
Authors:
- Heleen VellekoopHVHeleen Vellekoop
- Simone HuygensSHSimone Huygens
- Matthijs VersteeghMVMatthijs Versteegh
- László SzilberhornLSLászló Szilberhorn
- Tamás ZeleiTZTamás Zelei
- Balázs NagyBNBalázs Nagy
- Rositsa Koleva-KolarovaRKRositsa Koleva-Kolarova
- Sarah WordsworthSWSarah Wordsworth
- Maureen Rutten-Van MölkenMMMaureen Rutten-Van Mölken
- on behalf of the HEcoPerMed consortiumOCon behalf of the HEcoPerMed consortium
Open Access
- 1 July 2023
- journal article
- research article
- Published by Taylor & Francis in Personalized Medicine
- Vol. 20 (4) , 321-338
Abstract
Aim: To explore variations in the cost–effectiveness of entrectinib across different testing strategies and settings. Methods: Four testing strategies where adult cancer patients received entrectin... Plain language summary Histology-independent pharmaceuticals are a new phenomenon in cancer care. Most chemotherapies are prescribed based on the tumor's (primary) location, while histology-indepen...Keywords
Funding Information
- Horizon 2020 Framework Programme (824997)
This publication has 34 references indexed in Scilit:
- Strategies for Integrating Personalized Medicine into Healthcare PracticePersonalized Medicine, 2017
- Implementation of a Multicenter Biobanking Collaboration for Next-Generation Sequencing-Based Biomarker Discovery Based on Fresh Frozen Pretreatment Tumor Tissue BiopsiesThe Oncologist, 2017
- The Challenge of Conditional Reimbursement: Stopping Reimbursement Can Be More Difficult Than Not Starting in the First Place!Value in Health, 2017
- On the Estimation of the Cost-Effectiveness Threshold: Why, What, How?Value in Health, 2016
- Standardizing the Inclusion of Indirect Medical Costs in Economic EvaluationsPharmacoEconomics, 2011
- Genetic Tumor Profiling and Genetically Targeted Cancer TherapySeminars in Oncology Nursing, 2011
- Continuing the multiple sclerosis risk sharing scheme is unjustifiedBMJ, 2010
- Observational studies: a review of study designs, challenges and strategies to reduce confoundingInternational Journal Of Clinical Practice, 2009
- Confounding and confoundersOccupational and Environmental Medicine, 2003
- The friction cost method for measuring indirect costs of diseaseJournal of Health Economics, 1995